profit from every $100 of sales.
$0$100
Genenta Science
$0.63-3.03% today
-74.4% in 1 year
1-year low $0.581-year high $2.46
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Genenta Science sold, what it kept, and what it did with the cash.
Sales went from €0 in 2022 to €0 in 2025, with -€6.53 million of profit last year.
SalesProfit
Genenta Science vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Genenta Science | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Genenta Science's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -11 | -12 | -10 | -7 | |
| -11 | -12 | -10 | -7 | |
| -8 | -12 | -9 | -7 | |
| -0.47 | -0.64 | -0.49 | -0.33 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 33 | 22 | 15 | 32 |
| Cash | 30 | 4 | 5 | 6 |
| Total debt | – | – | – | 8 |
| Total liabilities | 2 | 2 | 2 | 10 |
| 31 | 20 | 12 | 22 | |
| 18 | 18 | 18 | 20 | |
| -28.0% | -45.4% | -61.7% | -17.7% | |
| -27.2% | -57.0% | -71.3% | -29.9% |
Cash flow
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -7 | -11 | -6 | -7 | |
| 0 | 0 | 0 | 0 | |
| -7 | -11 | -6 | -7 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 1 | 1 | 1 | 1 |
Valuation
- –
- –
- –
- 0.5×
- –
- –
- –
- -16.0%
- -14.6%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -21.3%
- -38.6%
- -36.8%
- -19.6%
- -21.3%
- –
Growth
- –
- –
- −10.1%
- –
- +2.0%
Financial health
- -0.3×
- 0.35
- 23.8%
- -17.0×
- 14.16
- 14.16
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 18%of 952
Bottom 20%of 883
Bottom 6%of 987
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Mar 31, 2026 | -0.36 | -0.36 | +0.0% |
| Feb 25, 2026 | -0.36 | -0.36 | +0.0% |
| Jun 30, 2024 | -0.24 | – | – |
| Apr 24, 2024 | -0.30 | -0.42 | +29.7% |
| Jun 30, 2023 | -0.40 | -0.41 | +3.2% |
| Apr 26, 2023 | -0.38 | – | – |
| Oct 7, 2022 | -0.12 | – | – |
| May 4, 2022 | -0.11 | – | – |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
29No pass
Benjamin Graham
71Pass
Philip Fisher
38No pass
Peter Lynch
54No pass
Joel Greenblatt
0No pass
Charlie Munger
32No pass
Terry Smith
36No pass
Questions about Genenta Science
Is Genenta Science a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Genenta Science AI analysis
What does Genenta Science do?
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. It is in Biotechnology.
Does Genenta Science pay a dividend?
No. Genenta Science does not pay a dividend at the moment.
Is Genenta Science stock halal?
Questionable. Genenta Science sits in a grey zone: short-term investments may earn interest; type not reported. How we check
How has Genenta Science stock done over the past year?
Down 74.4% over the past twelve months, to $0.63. It traded between $0.58 and $2.46 and is 74.4% below its high.
Who are Genenta Science's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Genenta Science's.
Prices: daily closes to Nov 6, 2026. Fundamentals: company reports via invest-like data.